862 related articles for article (PubMed ID: 11085200)
21. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
Martin RC; Scoggins CR; Schreeder M; Rilling WS; Laing CJ; Tatum CM; Kelly LR; Garcia-Monaco RD; Sharma VR; Crocenzi TS; Strasberg SM
Cancer; 2015 Oct; 121(20):3649-58. PubMed ID: 26149602
[TBL] [Abstract][Full Text] [Related]
22. Hepatic arterial infusion with oxaliplatin, folinic acid, and 5-fluorouracil in patients with hepatic metastases from colorectal cancer: role of carcino-embryonic antigen in assessment of response.
Kern W; Beckert B; Lang N; Waggershauser T; Braess J; Schalhorn A; Hiddemann W
Anticancer Res; 2000; 20(6D):4973-5. PubMed ID: 11326650
[TBL] [Abstract][Full Text] [Related]
23. Oxaliplatin in practice.
Misset JL
Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):4-7. PubMed ID: 9647612
[TBL] [Abstract][Full Text] [Related]
24. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E
J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of addition of bevacizumab to oxaliplatin-based preoperative chemotherapy in colorectal cancer with liver metastasis- a single institution experience.
Cvetanovic A; Vrbic S; Filipovic S; Pejcic I; Milenkovic D; Milenkovic N; Zivkovic N
J BUON; 2013; 18(3):641-6. PubMed ID: 24065477
[TBL] [Abstract][Full Text] [Related]
26. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy.
Sundar S; Symonds RP; Decatris MP; Kumar DM; Osman A; Vasanthan S; O'byrne KJ
Gynecol Oncol; 2004 Aug; 94(2):502-8. PubMed ID: 15297195
[TBL] [Abstract][Full Text] [Related]
28. New approaches to breast cancer: oxaliplatin combined with 5-fluorouracil and folinic acid in pretreated advanced breast cancer patients: preliminary reports.
Leonardi V; Savio G; Laudani A; Blasi L; Agostara B
Ann N Y Acad Sci; 2002 Jun; 963():91-7. PubMed ID: 12095933
[TBL] [Abstract][Full Text] [Related]
29. Hepatic arterial chemotherapy with oxaliplatin, folinic acid and 5-fluorouracil in pre-treated patients with liver metastases from colorectal cancer.
Del Freo A; Fiorentini G; Sanguinetti F; Muttini MP; Pennucci C; Mambrini A; Pacetti P; Della Seta R; Lombardi M; Torri T; Cantore M
In Vivo; 2006; 20(6A):743-6. PubMed ID: 17203759
[TBL] [Abstract][Full Text] [Related]
30. Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC).
Link K; Happich K; Schirner I; Jüngert B; Brückl V; Männlein G; Brückl WM; Merkel S; Göhl J; Hohenberger W; Hahn EG; Wein A
Anticancer Res; 2004; 24(1):385-91. PubMed ID: 15015625
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer.
Wein A; Riedel C; Brückl W; Merkel S; Ott R; Hanke B; Baum U; Fuchs F; Günther K; Reck T; Papadopoulos T; Hahn EG; Hohenberger W
Oncology; 2003; 64(2):131-8. PubMed ID: 12566910
[TBL] [Abstract][Full Text] [Related]
32. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.
Giacchetti S; Itzhaki M; Gruia G; Adam R; Zidani R; Kunstlinger F; Brienza S; Alafaci E; Bertheault-Cvitkovic F; Jasmin C; Reynes M; Bismuth H; Misset JL; Lévi F
Ann Oncol; 1999 Jun; 10(6):663-9. PubMed ID: 10442188
[TBL] [Abstract][Full Text] [Related]
33. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study.
Pectasides D; Pectasides M; Farmakis D; Gaglia A; Koumarianou A; Nikolaou M; Koumpou M; Kountourakis P; Papaxoinis G; Mitrou P; Economopoulos T; Raptis SA
Gynecol Oncol; 2004 Oct; 95(1):165-72. PubMed ID: 15385127
[TBL] [Abstract][Full Text] [Related]
34. The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study.
Carnaghi C; Santoro A; Rimassa L; Doci R; Rosati R; Pedicini V; Gullo G; Zuradelli M; Abbadessa G; Morenghi E; Marcon I; Garassino I
Invest New Drugs; 2007 Oct; 25(5):479-85. PubMed ID: 17492399
[TBL] [Abstract][Full Text] [Related]
35. Folfox4 regimen administered through combined hepatic arterial and systemic infusion for treatment of colorectal cancer with unresectable liver metastases.
Guan M; Chen SC; Ying HY; Zhao L; Li XY; Zhou JF; Shao YJ; Yang XD; Lin Y; Ning XH; Bai CM
Chin Med J (Engl); 2012 Oct; 125(20):3640-5. PubMed ID: 23075717
[TBL] [Abstract][Full Text] [Related]
36. Oxaliplatin for the treatment of advanced colorectal cancer: future directions.
Ducreux M; Louvet C; Bekradda M; Cvitkovic E
Semin Oncol; 1998 Apr; 25(2 Suppl 5):47-53. PubMed ID: 9609108
[TBL] [Abstract][Full Text] [Related]
37. Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies.
Lorenz M; Staib-Sebler E; Gog C; Proschek D; Jauch KW; Ridwelski K; Hohenberger W; Gassel HJ; Lehmann U; Vestweber KH; Padberg W; Zamzow K; Müller HH
Zentralbl Chir; 2003 Feb; 128(2):87-94. PubMed ID: 12632273
[TBL] [Abstract][Full Text] [Related]
38. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
39. A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma.
Correale P; Messinese S; Caraglia M; Marsili S; Piccolomini A; Petrioli R; Ceciarini F; Micheli L; Nencini C; Neri A; Vuolo G; Guarnieri A; Abbruzzese A; Prete SD; Giorgi G; Francini G
Br J Cancer; 2004 May; 90(9):1710-4. PubMed ID: 15150625
[TBL] [Abstract][Full Text] [Related]
40. Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients: original analysis of non-hematological toxicity and patient characteristics in a pilot investigation.
Farker K; Merkel U; Wedding U; Hippius M; Höffken K; Hoffmann A
Int J Clin Pharmacol Ther; 2006 Jan; 44(1):31-7. PubMed ID: 16425969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]